Whitney C G, Farley M M, Hadler J, Harrison L H, Lexau C, Reingold A, Lefkowitz L, Cieslak P R, Cetron M, Zell E R, Jorgensen J H, Schuchat A
Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, USA.
N Engl J Med. 2000 Dec 28;343(26):1917-24. doi: 10.1056/NEJM200012283432603.
The emergence of drug-resistant strains of bacteria has complicated treatment decisions and may lead to treatment failures.
We examined data on invasive pneumococcal disease in patients identified from 1995 to 1998 in the Active Bacterial Core Surveillance program of the Centers for Disease Control and Prevention. Pneumococci that had a high level of resistance or had intermediate resistance according to the definitions of the National Committee for Clinical Laboratory Standards were defined as "resistant" for this analysis.
During 1998, 4013 cases of invasive Streptococcus pneumoniae disease were reported (23 cases per 100,000 population); isolates were available for 3475 (87 percent). Overall, 24 percent of isolates from 1998 were resistant to penicillin. The proportion of isolates that were resistant to penicillin was highest in Georgia (33 percent) and Tennessee (35 percent), in children under five years of age (32 percent, vs. 21 percent for persons five or more years of age), and in whites (26 percent, vs. 22 percent for blacks). Penicillin-resistant isolates were more likely than susceptible isolates to have a high level of resistance to other antimicrobial agents. Serotypes included in the 7-valent conjugate and 23-valent pneumococcal polysaccharide vaccines accounted for 78 percent and 88 percent of penicillin-resistant strains, respectively. Between 1995 and 1998 (during which period 12,045 isolates were collected), the proportion of isolates that were resistant to three or more classes of drugs increased from 9 percent to 14 percent; there also were increases in the proportions of isolates that were resistant to penicillin (from 21 percent to 25 percent), cefotaxime (from 10 percent to 15 percent), meropenem (from 10 percent to 16 percent), erythromycin (from 11 percent to 16 percent), and trimethoprim-sulfamethoxazole (from 25 percent to 29 percent). The increases in the frequency of resistance to other antimicrobial agents occurred exclusively among penicillin-resistant isolates.
Multidrug-resistant pneumococci are common and are increasing. Because a limited number of serotypes account for most infections with drug-resistant strains, the new conjugate vaccines offer protection against most drug-resistant strains of S. pneumoniae.
耐药性细菌菌株的出现使治疗决策变得复杂,并可能导致治疗失败。
我们研究了1995年至1998年在美国疾病控制与预防中心的活性细菌核心监测项目中确诊的侵袭性肺炎球菌病患者的数据。根据美国国家临床实验室标准委员会的定义,具有高度耐药性或中度耐药性的肺炎球菌在本次分析中被定义为“耐药菌”。
1998年,共报告了4013例侵袭性肺炎链球菌病病例(每10万人中有23例);3475例(87%)分离株可用于分析。总体而言,1998年分离出的菌株中有24%对青霉素耐药。对青霉素耐药的菌株比例在佐治亚州(33%)和田纳西州(35%)最高,在5岁以下儿童中(32%,5岁及以上人群为21%)以及白人中(26%,黑人为22%)最高。耐青霉素分离株比敏感分离株更有可能对其他抗菌药物具有高度耐药性。7价结合疫苗和23价肺炎球菌多糖疫苗所包含的血清型分别占耐青霉素菌株的78%和88%。在1995年至1998年期间(共收集了12045株分离株),对三类或更多类药物耐药的分离株比例从9%增至14%;对青霉素耐药(从21%增至25%)、头孢噻肟(从10%增至15%)、美罗培南(从10%增至16%)、红霉素(从11%增至16%)和甲氧苄啶 - 磺胺甲恶唑(从25%增至29%)的分离株比例也有所增加。对其他抗菌药物耐药频率的增加仅发生在耐青霉素分离株中。
多重耐药肺炎球菌很常见且呈上升趋势。由于少数血清型占耐药菌株引起的大多数感染,新型结合疫苗可为大多数耐药肺炎链球菌菌株提供保护。